GeneOne Life Science's 51st EGM Proposes 80% Capital Reduction and Election of Three Inside Directors
GeneOne Life Science will hold its 51st Extraordinary General Meeting on April 30, 2026, to approve an 80% capital reduction through a 5:1 share consolidation to cover accumulated deficits.
The record date for the reduction is May 16, 2026, after which the capital will decrease to approximately 18.18 billion KRW.
The meeting also includes the election of three inside director candidates: Lee Joon-kyu, Jeon Kyung-ha, and Kim Hoon-beom.
[AI Summary]This capital reduction is intended to improve the financial structure but signals significant accumulated losses, which may negatively impact short-term stock sentiment. However, since it is a consolidation, proportional shareholder value is not diluted; the share price should adjust upward. While short-term price pressure is expected, the company may benefit from enhanced financial health in the long run.